Article(id=1330183552399946160, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1330183519441105099, articleNumber=null, orderNo=null, doi=10.16522/j.cnki.cjph.2023.02.005, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1669305600000, receivedDateStr=2022-11-25, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1795070072507, onlineDateStr=2026-11-19, pubDate=1675958400000, pubDateStr=2023-02-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1795070072507, onlineIssueDateStr=2026-11-19, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1795070072507, creator=13701087609, updateTime=1795070072507, updator=13701087609, issue=Issue{id=1330183519441105099, tenantId=1146029695717560320, journalId=1319690259887390882, year='2023', volume='54', issue='2', pageStart='165', pageEnd='294', issueExtLink='null', onlineDate='null', pubDate='1675958400000', pubDateStr='2023-02-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1795070064649, creator='13701087609', updateTime=1795080429540, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1330226993464979643, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1330183519441105099, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1330226993464979644, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1330183519441105099, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=200, endPage=206, ext={EN=ArticleExt(id=1330183552706130353, articleId=1330183552399946160, tenantId=1146029695717560320, journalId=1319690259887390882, language=EN, title=Analysis of Preparation Technology of Three mRNA Vaccines, columnId=1327671134809600231, journalTitle=Chinese Journal of Pharmaceuticals, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Compared with traditional inactivated vaccines, mRNA vaccines have strong immunogenicity and can activate both humoral and cellular immunity. In addition, it has the advantages of a short development cycle, broad neutralization breadth, low cost, and a relatively simple manufacturing process that can be rapidly scaled to respond to sudden and rapidly mutating pandemic outbreaks. As a new vaccine technology, mRNA vaccines have many novel features and challenges. Taking the three coronavirus disease 2019(COVID-19) vaccines, BNT162b2 from Pfizer/BioNTech, mRNA-1273 from Moderna, and ARCoV developed by several Chinese institutions, as examples, this paper summarizes and analyzes the development and manufacturing strategy for mRNA vaccines in terms of antigen selection, nucleoside modification, and lipid nanoparticles(LNP) formulation preparation. The current challenges and future directions are discussed to contribute to a better understanding of mRNA vaccine technology.

, authors=Hongwei CHANG1, Long XU2, authorsList=Hongwei CHANG, Long XU, authorCompany=null, correspAuthors=null, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1330183553389801906, articleId=1330183552399946160, tenantId=1146029695717560320, journalId=1319690259887390882, language=CN, title=三款mRNA疫苗制备工艺技术分析, columnId=1327671135019315436, journalTitle=中国医药工业杂志, columnName=综述, runingTitle=null, highlight=null, articleAbstract=

与传统的灭活疫苗相比,mRNA疫苗免疫原性强,可同时激活体液免疫和细胞免疫,另外还具有开发周期短、广谱性、成本低和可大规模快速量产等优势,可有效应对突发性、变异快以及大规模的疫情。作为一种新的疫苗开发路径,mRNA疫苗在技术工艺上有很多新的特色和挑战。该研究以Pfizer/BioNTech公司的mRNA疫苗BNT162b2、Moderna公司的mRNA-1273,以及国内多家单位联合开发的ARCoV这3款新型冠状病毒疫苗为例,从抗原选择、核苷修饰及脂质体纳米颗粒(LNP)制剂制备等方面,对mRNA疫苗的开发设计和制备工艺进行了梳理分析,并讨论了当前面临的挑战和未来的发展方向,旨在为mRNA疫苗技术的开发和应用提供参考。

, authors=常洪委1, 许龙2, authorsList=常洪委, 许龙, authorCompany=null, correspAuthors=null, authorNote=

常洪委(1987—),男,硕士,从事药物研发和制药工艺研究。E-mail:

, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=BOO66acE+x3jFgbuJk2W5Q==, magXml=IBGnVqXFHw/OMmN+KTaYuA==, pdfUrl=null, pdf=PgdPp/SbOR3/h8hHMw92yw==, pdfFileSize=1682495, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=YpsycJWFPuw5mJ7x8qdCYQ==, mapNumber=null, fund=null)}, authors=[Author(id=1330183554929111488, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=chhwzhiyao@163.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330183555004608962, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, authorId=1330183554929111488, language=EN, stringName=Hongwei CHANG, firstName=Hongwei, middleName=null, lastName=CHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Taizhou Medical Hi-Tech Zone Public Service Platform, Taizhou 225300, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330183555084300739, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, authorId=1330183554929111488, language=CN, stringName=常洪委, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.泰州市医药高新技术产业园区公共平台服务中心,江苏 泰州 225300, bio={"content":"

常洪委(1987—),男,硕士,从事药物研发和制药工艺研究。E-mail:

"}, bioImg=null, bioContent=

常洪委(1987—),男,硕士,从事药物研发和制药工艺研究。E-mail:

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330183554744562104, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, xref=1., ext=[AuthorCompanyExt(id=1330183554757145017, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, companyId=1330183554744562104, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Taizhou Medical Hi-Tech Zone Public Service Platform, Taizhou 225300), AuthorCompanyExt(id=1330183554782310842, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, companyId=1330183554744562104, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.泰州市医药高新技术产业园区公共平台服务中心,江苏 泰州 225300)])]), Author(id=1330183555151409605, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330183555239489991, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, authorId=1330183555151409605, language=EN, stringName=Long XU, firstName=Long, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai Biointron Biological Inc., Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330183555310793160, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, authorId=1330183555151409605, language=CN, stringName=许龙, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海百英生物科技股份有限公司,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330183554845225403, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, xref=2., ext=[AuthorCompanyExt(id=1330183554853614012, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, companyId=1330183554845225403, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Biointron Biological Inc., Shanghai 201203), AuthorCompanyExt(id=1330183554857808317, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, companyId=1330183554845225403, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海百英生物科技股份有限公司,上海 201203)])])], keywords=[Keyword(id=1330183555411456457, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, language=EN, orderNo=1, keyword=mRNA vaccine), Keyword(id=1330183555520508362, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, language=EN, orderNo=2, keyword=antigen selection), Keyword(id=1330183555608588748, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, language=EN, orderNo=3, keyword=nucleoside modification), Keyword(id=1330183555679891917, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, language=EN, orderNo=4, keyword=delivery system), Keyword(id=1330183555738612174, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, language=CN, orderNo=1, keyword=mRNA疫苗), Keyword(id=1330183555864441295, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, language=CN, orderNo=2, keyword=抗原选择), Keyword(id=1330183555935744464, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, language=CN, orderNo=3, keyword=核苷修饰), Keyword(id=1330183556082545105, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, language=CN, orderNo=4, keyword=递送系统)], refs=[Reference(id=1330183556254511571, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=POLACK F P, THOMAS S J, KITCHIN N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine [J]. N Engl J Med, 2020, 383(27): 2603-2615., articleTitle=null, refAbstract=null), Reference(id=1330183556367757781, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=BADEN L R, EL SAHLY H M, ESSINK B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine [J]. N Engl J Med, 2021, 384(5): 403-416., articleTitle=null, refAbstract=null), Reference(id=1330183556426478038, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=AMANAT F, KRAMMER F. SARS-CoV-2 vaccines: status report [J]. Immunity, 2020, 52(4): 583-589., articleTitle=null, refAbstract=null), Reference(id=1330183556510364119, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=BENTON D J, WROBEL A G , XU P Q, et al. Receptor binding and priming of the spike protein of SAR-CoV-2 for membrane fusion [J]. Nature, 2020, 588(7837): 327-330., articleTitle=null, refAbstract=null), Reference(id=1330183556598444504, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=WRAPP D, WANG N S, CORBETT K S, et al. Cryo-EM Structure of the 2019-nCoV spike in the prefusion conformation [J]. Science, 2020, 367(6483): 1260-1263., articleTitle=null, refAbstract=null), Reference(id=1330183556720079321, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=WALLS A C, PARK Y J, TORTORICI M A , et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein [J]. Cell, 2020, 181(2): 281-292., articleTitle=null, refAbstract=null), Reference(id=1330183556799771098, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=PALLESEN J, WANG N S, CORBETT K S , et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen [J]. Proc Natl Acad Sci U S A, 2017, 114(35): E7348-E7357., articleTitle=null, refAbstract=null), Reference(id=1330183556875268571, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=BioNTech. BNT162 COVID-19 vaccine update call [EB/OL]. [2022-11-25]. https://investors.biontech.de/static-files/c4feb567-e564-40e5-a9cf-538892af1c04., articleTitle=null, refAbstract=null), Reference(id=1330183556950766044, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=WALSH E E, FRENCK R W Jr, FALSEY A R, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates [J]. N Engl J Med, 2020, 383(25): 2439-2450., articleTitle=null, refAbstract=null), Reference(id=1330183557051429341, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=GREANEY A J, LOES A N, GENTLES L E, et al. Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection [J]. Sci Transl Med, 2021, 13(600):eabi9915., articleTitle=null, refAbstract=null), Reference(id=1330183557135315422, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHANG N N, LI X F, DENG Y Q, et al. A thermostable mRNA vaccine against COVID-19 [J]. Cell, 2020, 182(5):1271-1283., articleTitle=null, refAbstract=null), Reference(id=1330183557227590111, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=VOGEL A B, KANEVSKY I, CHE Y, et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2 [J]. Nature, 2021, 592(7853): 283-289., articleTitle=null, refAbstract=null), Reference(id=1330183557286310368, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=KIM J, EYGERIS Y, GUPTA M, et al. Self-assembled mRNA vaccines [J]. Adv Drug Deliv Rev, 2021, 170: 83-112., articleTitle=null, refAbstract=null), Reference(id=1330183557349224929, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Moderna. First participants dosed in phase 1 study evaluating mRNA-1283, Moderna's next generation COVID-19 vaccine [EB/OL]. [2022-11-25]. https://investors.modernatx.com/news-releases/news-release-details/first-participants-dosed-phase-1-study-evaluating-mrna-1283., articleTitle=null, refAbstract=null), Reference(id=1330183557412139490, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=SCHOENMAKER L, WITZIGMANN D, KULKARNI J A, et al. mRNA-lipid nanoparticle COVID-19 vaccines:structure and stability [J]. Int J Pharm, 2021, 601:120586., articleTitle=null, refAbstract=null), Reference(id=1330183557487636963, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=KARIKÓ K, BUCKSTEIN M, NI H, et al. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA[J]. Immunity, 2005, 23(2): 165-175., articleTitle=null, refAbstract=null), Reference(id=1330183557567328740, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=KARIKÓ K, MURAMATSU H, WELSH F A, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability [J]. Mol Ther, 2008, 16(11): 1833-1840., articleTitle=null, refAbstract=null), Reference(id=1330183559169552871, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=ANDRIES O, CAFFERTY S M, DE SMEDT S C, et al. N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice [J]. J Control Release,2015, 217: 337-344., articleTitle=null, refAbstract=null), Reference(id=1330183559245050344, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=CORBETT K S, FLYNN B, FOULDS K E, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates [J]. N Engl J Med, 2020, 383(16):1544-1555., articleTitle=null, refAbstract=null), Reference(id=1330183559316353513, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=HASSETT K J , BENENATO K E, JACQUINET E, et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines [J]. Mol Ther Nucleic Acids, 2019, 15: 1-11., articleTitle=null, refAbstract=null), Reference(id=1330183559412822507, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=EDWARD Y, KIEU L, LLOYD J, et al. Lipid formulations for nucleic acid delivery: US, 9364435B2 [P]. 2016-06-14., articleTitle=null, refAbstract=null), Reference(id=1330183559530263019, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=EDWARD Y, KIEU L, LLOYD J, et al. Lipid formulations for nucleic acid delivery: US, 8058069B2 [P]. 2011-11-15., articleTitle=null, refAbstract=null), Reference(id=1330183559584788972, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=AKINC A, MAIER M A , MANOHARAN M, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs [J]. Nat Nanotechnol,2019, 14(12): 1084-1087., articleTitle=null, refAbstract=null), Reference(id=1330183559651897837, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=HOU X C, ZAKS T, LANGER R, et al. Lipid nanoparticles for mRNA delivery [J]. Nat Rev Mater, 2021, 6(12):1078-1094., articleTitle=null, refAbstract=null), Reference(id=1330183559719006702, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=英博,王秀莲.一种阳离子脂质化合物、包含其的组合物及应用:中国,112979483A [P].2021-06-18., articleTitle=null, refAbstract=null), Reference(id=1330183559798698479, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=JUDGE A, MCCLINTOCK K, PHELPS J R, et al. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes [J]. Mol Ther,2006, 13(2): 328-337., articleTitle=null, refAbstract=null), Reference(id=1330183559865807344, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=SEMPLE S C, LEONE R, BARBOSA C J, et al. Lipid nanoparticle delivery systems to enable mRNA-based therapeutics [J]. Pharmaceutics, 2022, 14(2): 398., articleTitle=null, refAbstract=null), Reference(id=1330183559924527601, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=NICULESCU A, BÎRCĂ A C, GRUMEZESCU A M . New applications of lipid and polymer-based nanoparticles for nucleic acids delivery [J]. Pharmaceutics, 2021, 13(12):2053., articleTitle=null, refAbstract=null), Reference(id=1330183559995830770, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=LBARTA I, HOFFMAN S, SIMPKINS A. Manufacturing strategy for the production of 200 million sterile doses of an mRNA vaccine for COVID-19 [EB/OL]. [2022-11-25]. https://repository.upenn.edu/cgi/viewcontent.cgi?article=1132&context=cbe_sdr., articleTitle=null, refAbstract=null), Reference(id=1330183560054551027, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=ANDREWS N, STOWE J, KIRSEBOM F, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant [J]. N Engl J Med, 2022, 386(16): 1532-1546., articleTitle=null, refAbstract=null), Reference(id=1330183560121659892, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG K, JIA Z J, BAO L L, et al. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants [J]. Nature, 2022, 603: 919-925., articleTitle=null, refAbstract=null), Reference(id=1330183560205545973, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=LI C, ZHAN W Q, YANG Z L, et al. Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody [J]. Cell, 2022, 185(8): 1389-1401., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1330183554744562104, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, xref=1., ext=[AuthorCompanyExt(id=1330183554757145017, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, companyId=1330183554744562104, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Taizhou Medical Hi-Tech Zone Public Service Platform, Taizhou 225300), AuthorCompanyExt(id=1330183554782310842, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, companyId=1330183554744562104, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.泰州市医药高新技术产业园区公共平台服务中心,江苏 泰州 225300)]), AuthorCompany(id=1330183554845225403, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, xref=2., ext=[AuthorCompanyExt(id=1330183554853614012, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, companyId=1330183554845225403, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Biointron Biological Inc., Shanghai 201203), AuthorCompanyExt(id=1330183554857808317, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, companyId=1330183554845225403, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海百英生物科技股份有限公司,上海 201203)])], figs=null, attaches=null, journal=Journal(id=1319689822849302687, delFlag=0, nameCn=中国医药工业杂志, nameEn=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, issn=1001-8255, eissn=null, cn=31-1243/R, coden=ZYGZEA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=etiWDuwx2KO274LHw88KJA==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of Pharmaceuticals, journalRemark=null, publicationField=null, createdTime=1792568172420, updatedTime=1792747450744, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=etiWDuwx2KO274LHw88KJA==, picEn=ip9NF4dK57AmNrCiZ6hmdw==, jcr=null, cjcr=null, exts=[JournalExt(id=1320441770761105589, language=CN, name=中国医药工业杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450771, updatedTime=1792747450771, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""}), JournalExt(id=1320441770819825846, language=EN, name=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450785, updatedTime=1792747450785, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""})], databaseList=null, tenantJournalId=1319690259887390882, websiteList=[Website(id=1319720771623174732, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/CN, language=CN, createTime=1792575551181, createBy=18614031015, updateTime=1792746040843, updateBy=18614031015, name=中国医药工业杂志-中文, tplId=1146099689490845704, title=中国医药工业杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428487504769041, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=articleTextType, value=kx, createTime=1792982702375, updateTime=1792982702375, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487475408910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982702368, updateTime=1792982702368, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487538323476, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=grayFlag, value=0, createTime=1792982702383, updateTime=1792982702383, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487462825997, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982702365, updateTime=1792982702365, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487571877910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=minRunFlag, value=0, createTime=1792982702391, updateTime=1792982702391, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487496380432, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic, createTime=1792982702373, updateTime=1792982702373, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487563489301, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=silenceFlag, value=0, createTime=1792982702389, updateTime=1792982702389, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487483797519, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982702370, updateTime=1792982702370, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487517351954, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeColor, value=null, createTime=1792982702378, updateTime=1792982702378, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487525740563, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982702380, updateTime=1792982702380, creator=18614031015, updator=18614031015)]), Website(id=1319720771702866512, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/EN, language=EN, createTime=1792575551200, createBy=18614031015, updateTime=1792746037543, updateBy=18614031015, name=中国医药工业杂志-英文, tplId=1146101810881728533, title=Chinese Journal of Pharmaceuticals, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428509638111261, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=articleTextType, value=kx, createTime=1792982707652, updateTime=1792982707652, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509579391002, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982707638, updateTime=1792982707638, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509680054304, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=grayFlag, value=0, createTime=1792982707662, updateTime=1792982707662, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509566808089, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982707635, updateTime=1792982707635, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509701025826, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=minRunFlag, value=0, createTime=1792982707667, updateTime=1792982707667, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509629722652, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic, createTime=1792982707650, updateTime=1792982707650, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509688442913, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=silenceFlag, value=0, createTime=1792982707664, updateTime=1792982707664, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509587779611, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982707640, updateTime=1792982707640, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509663277086, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeColor, value=null, createTime=1792982707658, updateTime=1792982707658, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509671665695, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982707660, updateTime=1792982707660, creator=18614031015, updator=18614031015)])], journalTitle=中国医药工业杂志, weixinUrl=null, journalUrl=http://www.cjph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of Pharmaceuticals, journalPhotoCn=etiWDuwx2KO274LHw88KJA==, journalPhotoEn=ip9NF4dK57AmNrCiZ6hmdw==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2023.02.005, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2023.02.005, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/PDF/10.16522/j.cnki.cjph.2023.02.005, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/PDF/10.16522/j.cnki.cjph.2023.02.005, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1675958400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
三款mRNA疫苗制备工艺技术分析
常洪委 1 , 许龙 2
中国医药工业杂志 | 综述 2023,54(2): 200-206
收起
收藏切换
中国医药工业杂志 |综述 2023 , 54 (2) : 200 -206
三款mRNA疫苗制备工艺技术分析
全屏
[Author(id=1330183554929111488, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=chhwzhiyao@163.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330183555004608962, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, authorId=1330183554929111488, language=EN, stringName=Hongwei CHANG, firstName=Hongwei, middleName=null, lastName=CHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Taizhou Medical Hi-Tech Zone Public Service Platform, Taizhou 225300, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330183555084300739, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, authorId=1330183554929111488, language=CN, stringName=常洪委, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.泰州市医药高新技术产业园区公共平台服务中心,江苏 泰州 225300, bio={"content":"

常洪委(1987—),男,硕士,从事药物研发和制药工艺研究。E-mail:

"}, bioImg=null, bioContent=

常洪委(1987—),男,硕士,从事药物研发和制药工艺研究。E-mail:

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330183554744562104, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, xref=1., ext=[AuthorCompanyExt(id=1330183554757145017, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, companyId=1330183554744562104, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Taizhou Medical Hi-Tech Zone Public Service Platform, Taizhou 225300), AuthorCompanyExt(id=1330183554782310842, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, companyId=1330183554744562104, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.泰州市医药高新技术产业园区公共平台服务中心,江苏 泰州 225300)])]), Author(id=1330183555151409605, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330183555239489991, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, authorId=1330183555151409605, language=EN, stringName=Long XU, firstName=Long, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai Biointron Biological Inc., Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330183555310793160, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, authorId=1330183555151409605, language=CN, stringName=许龙, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海百英生物科技股份有限公司,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330183554845225403, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, xref=2., ext=[AuthorCompanyExt(id=1330183554853614012, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, companyId=1330183554845225403, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Biointron Biological Inc., Shanghai 201203), AuthorCompanyExt(id=1330183554857808317, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1330183552399946160, companyId=1330183554845225403, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海百英生物科技股份有限公司,上海 201203)])])]
常洪委1 , 许龙2
作者信息
  • 1.泰州市医药高新技术产业园区公共平台服务中心,江苏 泰州 225300
  • 2.上海百英生物科技股份有限公司,上海 201203
作者简介:

常洪委(1987—),男,硕士,从事药物研发和制药工艺研究。E-mail:

Analysis of Preparation Technology of Three mRNA Vaccines
Hongwei CHANG1 , Long XU2
Affiliations
  • 1.Taizhou Medical Hi-Tech Zone Public Service Platform, Taizhou 225300
  • 2.Shanghai Biointron Biological Inc., Shanghai 201203
出版时间: 2023-02-10 doi: 10.16522/j.cnki.cjph.2023.02.005
文章导航
收藏切换

与传统的灭活疫苗相比,mRNA疫苗免疫原性强,可同时激活体液免疫和细胞免疫,另外还具有开发周期短、广谱性、成本低和可大规模快速量产等优势,可有效应对突发性、变异快以及大规模的疫情。作为一种新的疫苗开发路径,mRNA疫苗在技术工艺上有很多新的特色和挑战。该研究以Pfizer/BioNTech公司的mRNA疫苗BNT162b2、Moderna公司的mRNA-1273,以及国内多家单位联合开发的ARCoV这3款新型冠状病毒疫苗为例,从抗原选择、核苷修饰及脂质体纳米颗粒(LNP)制剂制备等方面,对mRNA疫苗的开发设计和制备工艺进行了梳理分析,并讨论了当前面临的挑战和未来的发展方向,旨在为mRNA疫苗技术的开发和应用提供参考。

mRNA疫苗  /  抗原选择  /  核苷修饰  /  递送系统

Compared with traditional inactivated vaccines, mRNA vaccines have strong immunogenicity and can activate both humoral and cellular immunity. In addition, it has the advantages of a short development cycle, broad neutralization breadth, low cost, and a relatively simple manufacturing process that can be rapidly scaled to respond to sudden and rapidly mutating pandemic outbreaks. As a new vaccine technology, mRNA vaccines have many novel features and challenges. Taking the three coronavirus disease 2019(COVID-19) vaccines, BNT162b2 from Pfizer/BioNTech, mRNA-1273 from Moderna, and ARCoV developed by several Chinese institutions, as examples, this paper summarizes and analyzes the development and manufacturing strategy for mRNA vaccines in terms of antigen selection, nucleoside modification, and lipid nanoparticles(LNP) formulation preparation. The current challenges and future directions are discussed to contribute to a better understanding of mRNA vaccine technology.

mRNA vaccine  /  antigen selection  /  nucleoside modification  /  delivery system
常洪委, 许龙. 三款mRNA疫苗制备工艺技术分析. 中国医药工业杂志, 2023 , 54 (2) : 200 -206 . DOI: 10.16522/j.cnki.cjph.2023.02.005
Hongwei CHANG, Long XU. Analysis of Preparation Technology of Three mRNA Vaccines[J]. Chinese Journal of Pharmaceuticals, 2023 , 54 (2) : 200 -206 . DOI: 10.16522/j.cnki.cjph.2023.02.005

参考文献 引证文献
排序方式:
[1]
POLACK F P, THOMAS S J, KITCHIN N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine [J]. N Engl J Med, 2020, 383(27): 2603-2615.
[2]
BADEN L R, EL SAHLY H M, ESSINK B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine [J]. N Engl J Med, 2021, 384(5): 403-416.
[3]
AMANAT F, KRAMMER F. SARS-CoV-2 vaccines: status report [J]. Immunity, 2020, 52(4): 583-589.
[4]
BENTON D J, WROBEL A G , XU P Q, et al. Receptor binding and priming of the spike protein of SAR-CoV-2 for membrane fusion [J]. Nature, 2020, 588(7837): 327-330.
[5]
WRAPP D, WANG N S, CORBETT K S, et al. Cryo-EM Structure of the 2019-nCoV spike in the prefusion conformation [J]. Science, 2020, 367(6483): 1260-1263.
[6]
WALLS A C, PARK Y J, TORTORICI M A , et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein [J]. Cell, 2020, 181(2): 281-292.
[7]
PALLESEN J, WANG N S, CORBETT K S , et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen [J]. Proc Natl Acad Sci U S A, 2017, 114(35): E7348-E7357.
[8]
BioNTech. BNT162 COVID-19 vaccine update call [EB/OL]. [2022-11-25]. https://investors.biontech.de/static-files/c4feb567-e564-40e5-a9cf-538892af1c04.
[9]
WALSH E E, FRENCK R W Jr, FALSEY A R, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates [J]. N Engl J Med, 2020, 383(25): 2439-2450.
[10]
GREANEY A J, LOES A N, GENTLES L E, et al. Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection [J]. Sci Transl Med, 2021, 13(600):eabi9915.
[11]
ZHANG N N, LI X F, DENG Y Q, et al. A thermostable mRNA vaccine against COVID-19 [J]. Cell, 2020, 182(5):1271-1283.
[12]
VOGEL A B, KANEVSKY I, CHE Y, et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2 [J]. Nature, 2021, 592(7853): 283-289.
[13]
KIM J, EYGERIS Y, GUPTA M, et al. Self-assembled mRNA vaccines [J]. Adv Drug Deliv Rev, 2021, 170: 83-112.
[14]
Moderna. First participants dosed in phase 1 study evaluating mRNA-1283, Moderna's next generation COVID-19 vaccine [EB/OL]. [2022-11-25]. https://investors.modernatx.com/news-releases/news-release-details/first-participants-dosed-phase-1-study-evaluating-mrna-1283.
[15]
SCHOENMAKER L, WITZIGMANN D, KULKARNI J A, et al. mRNA-lipid nanoparticle COVID-19 vaccines:structure and stability [J]. Int J Pharm, 2021, 601:120586.
[16]
KARIKÓ K, BUCKSTEIN M, NI H, et al. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA[J]. Immunity, 2005, 23(2): 165-175.
[17]
KARIKÓ K, MURAMATSU H, WELSH F A, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability [J]. Mol Ther, 2008, 16(11): 1833-1840.
[18]
ANDRIES O, CAFFERTY S M, DE SMEDT S C, et al. N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice [J]. J Control Release,2015, 217: 337-344.
[19]
CORBETT K S, FLYNN B, FOULDS K E, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates [J]. N Engl J Med, 2020, 383(16):1544-1555.
[20]
HASSETT K J , BENENATO K E, JACQUINET E, et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines [J]. Mol Ther Nucleic Acids, 2019, 15: 1-11.
[21]
EDWARD Y, KIEU L, LLOYD J, et al. Lipid formulations for nucleic acid delivery: US, 9364435B2 [P]. 2016-06-14.
[22]
EDWARD Y, KIEU L, LLOYD J, et al. Lipid formulations for nucleic acid delivery: US, 8058069B2 [P]. 2011-11-15.
[23]
AKINC A, MAIER M A , MANOHARAN M, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs [J]. Nat Nanotechnol,2019, 14(12): 1084-1087.
[24]
HOU X C, ZAKS T, LANGER R, et al. Lipid nanoparticles for mRNA delivery [J]. Nat Rev Mater, 2021, 6(12):1078-1094.
[25]
英博,王秀莲.一种阳离子脂质化合物、包含其的组合物及应用:中国,112979483A [P].2021-06-18.
[26]
JUDGE A, MCCLINTOCK K, PHELPS J R, et al. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes [J]. Mol Ther,2006, 13(2): 328-337.
[27]
SEMPLE S C, LEONE R, BARBOSA C J, et al. Lipid nanoparticle delivery systems to enable mRNA-based therapeutics [J]. Pharmaceutics, 2022, 14(2): 398.
[28]
NICULESCU A, BÎRCĂ A C, GRUMEZESCU A M . New applications of lipid and polymer-based nanoparticles for nucleic acids delivery [J]. Pharmaceutics, 2021, 13(12):2053.
[29]
LBARTA I, HOFFMAN S, SIMPKINS A. Manufacturing strategy for the production of 200 million sterile doses of an mRNA vaccine for COVID-19 [EB/OL]. [2022-11-25]. https://repository.upenn.edu/cgi/viewcontent.cgi?article=1132&context=cbe_sdr.
[30]
ANDREWS N, STOWE J, KIRSEBOM F, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant [J]. N Engl J Med, 2022, 386(16): 1532-1546.
[31]
WANG K, JIA Z J, BAO L L, et al. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants [J]. Nature, 2022, 603: 919-925.
[32]
LI C, ZHAN W Q, YANG Z L, et al. Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody [J]. Cell, 2022, 185(8): 1389-1401.
2023年第54卷第2期
18
3
0
引用本文
BibTeX
文章信息
doi: 10.16522/j.cnki.cjph.2023.02.005
  • 接收时间:2022-11-25
  • 首发时间:2026-11-19
  • 出版时间:2023-02-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2022-11-25
基金
作者信息
    1.泰州市医药高新技术产业园区公共平台服务中心,江苏 泰州 225300
    2.上海百英生物科技股份有限公司,上海 201203
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2023.02.005
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏